Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Marimed (MRMD) over the last 15 years, with Q3 2025 value amounting to $6.6 million.

  • Marimed's Cash & Equivalents fell 3261.14% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year decrease of 3261.14%. This contributed to the annual value of $7.3 million for FY2024, which is 5027.65% down from last year.
  • As of Q3 2025, Marimed's Cash & Equivalents stood at $6.6 million, which was down 3261.14% from $6.1 million recorded in Q2 2025.
  • In the past 5 years, Marimed's Cash & Equivalents registered a high of $33.5 million during Q1 2022, and its lowest value of $6.1 million during Q2 2025.
  • Its 5-year average for Cash & Equivalents is $14.4 million, with a median of $12.3 million in 2021.
  • As far as peak fluctuations go, Marimed's Cash & Equivalents surged by 103121.67% in 2021, and later tumbled by 6719.67% in 2022.
  • Quarter analysis of 5 years shows Marimed's Cash & Equivalents stood at $29.7 million in 2021, then tumbled by 67.2% to $9.7 million in 2022, then soared by 50.41% to $14.6 million in 2023, then tumbled by 50.28% to $7.3 million in 2024, then fell by 9.42% to $6.6 million in 2025.
  • Its last three reported values are $6.6 million in Q3 2025, $6.1 million for Q2 2025, and $7.2 million during Q1 2025.